• In late June 2026, FTSE Russell removed Teladoc Health, Inc. from several key growth and small‑cap benchmarks, including the Russell 2000 Growth and Russell 3000 Growth indexes.
• This wave of index removals comes as Teladoc faces flat near‑term sales estimates and pressure on average revenue per user, highlighting investor concerns about its growth profile.
• We’ll now examine how Teladoc’s removal from multiple Russell growth indexes may influence its investment narrative and future positioning.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Teladoc Health Investment Narrative Recap

To own Teladoc today, you have to believe virtual care can still compound value even with slower growth, flat near term sales estimates, and pressure on average revenue per user. The Russell index removals highlight how quickly sentiment can shift, but they do not, by themselves, alter the key near term catalyst, which is Teladoc’s ability to stabilize revenue and margins in BetterHelp and chronic care, or the biggest risk, that these segments continue to face pricing and retention pressure.

The Walmart Better Care Services partnership announced in May 2026 looks particularly relevant here, as it directly targets user access and visit volume at a time when Teladoc is under scrutiny for weak monetization and ARPU trends. By expanding virtual urgent care, dermatology, nutrition, and BetterHelp access across Walmart’s platform, Teladoc is leaning into its core catalyst of expanding paid engagement, even as recent index removals put more attention on whether that engagement can translate into healthier revenue per user.

Yet beneath this, investors should also be aware that pressure on BetterHelp’s U.S. cash pay business and the shift to lower margin insurance revenue could...

Teladoc Health's narrative projects $2.6 billion revenue and $173.1 million earnings by 2029. This implies flat yearly revenue growth and a $344.2 million earnings increase from -$171.1 million today.

Uncover how Teladoc Health's forecasts yield a $7.40 fair value, a 22% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts expected Teladoc to reach about US$2.7 billion in revenue and positive earnings by 2029, yet this contrasts sharply with concerns that the shift to pay per visit and insurance based models could keep margins under pressure, showing how widely views can differ and why fresh index removal news may prompt you to revisit which version of Teladoc’s future you really believe in.

Explore 4 other fair value estimates on Teladoc Health - why the stock might be worth as much as 58% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Teladoc Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teladoc Health's overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.